ClinicalTrials.gg
CompletedNCT06627413Updated Jul 31, 2026

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

A Phase 1 interventional study of Lumateperone Capsule and Lumateperone LAI in Schizophrenia or Schizoaffective, sponsored by Intra-Cellular Therapies, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.

Enrollment
7th of 12
52 · median 66
Started
2024
with 3 others
Phase 1
3 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
9 of 12
Intra-Cellular Therapies, Inc.

Among the 12 studies testing lumateperone in Schizophrenia, this one is the 7th largest by enrollment, is one of 4 that started in 2024, is one of 3 in phase 1, and was the 12th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lumateperone

lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing lumateperone in Schizophrenia, or all of them as a file.
02

Study summary

Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.

03

Conditions studied

  • Schizophrenia or Schizoaffective

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Male or female patients between 18 and 55 years of age, inclusive;
  • Clinical diagnosis of schizophrenia or schizoaffective disorder according to (DSM-5);
  • Clinically stable and free from acute exacerbation of psychosis for at least 3 months prior to Screening;
  • Clinical Global Impression - Severity (CGI-S) score ≤ 3 at Screening and prior to dosing on Day 1;
  • (BMI) between 18.0 and 38.0 kg/m2, inclusive at Screening, and a minimum body weight of 50 kg at Screening.

Main Exclusion Criteria:

  • History of psychiatric condition other than schizophrenia that, in the Investigator's opinion, may be detrimental to participation in the study;
  • Any suicidal ideation or wish to be dead within the past 6 months of Screening, any suicide attempt within the past 2 years prior to Screening, or any current concern for the patient's safety based on the Columbia-Suicide Severity Rating Scale (C-SSRS) (excluding self-injurious, non-suicidal behavior), and/or Investigator assessment that the patient is a safety risk to him/herself or others;
  • abnormality within 2 years of Screening that in the Investigator's opinion may place the patient at risk or interfere with study outcome variables;
  • Has a corrected for heart rate using Fridericia formula > 450 msec in males or > 470 msec in females, or evidence of clinically significant bundle branch blocks on at Screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-E2 after a 5-day washout

    Drug: Lumateperone Capsule · Drug: Lumateperone LAI

  • Experimental
    Cohort 2

    Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-E3 after a 5-day washout

    Drug: Lumateperone Capsule · Drug: Lumateperone LAI

  • Experimental
    Cohort 3

    Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-X2 after a 5-day washout

    Drug: Lumateperone Capsule · Drug: Lumateperone LAI

  • Experimental
    Cohort 4

    Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-X5 after a 5-day washout

    Drug: Lumateperone Capsule · Drug: Lumateperone LAI

  • Experimental
    Cohort 5

    Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> 100 mg) of lumateperone LAI formulation (chosen from Part A) after a 5-day washout

    Drug: Lumateperone Capsule · Drug: Lumateperone LAI

  • Experimental
    Cohort 6

    Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> 100 mg) of lumateperone LAI formulation (chosen from Part A) after a 5-day washout

    Drug: Lumateperone Capsule · Drug: Lumateperone LAI

  • Experimental
    Cohort 7

    Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> 100 mg) of lumateperone LAI formulation (chosen from Part A) after a 5-day washout

    Drug: Lumateperone Capsule · Drug: Lumateperone LAI

  • Experimental
    Cohort 8

    Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> dose in Part B) of lumateperone LAI formulation (chosen from Part B) after a 5-day washout

    Drug: Lumateperone Capsule · Drug: Lumateperone LAI

  • Experimental
    Cohort 9

    Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> dose in Part B) of lumateperone LAI formulation (chosen from Part B) after a 5-day washout

    Drug: Lumateperone Capsule · Drug: Lumateperone LAI

Interventions

  • Lumateperone 42 mg capsule, oral administration

  • DrugLumateperone LAI

    Lumateperone LAI X500-E2 IM injection

  • DrugLumateperone LAI

    Lumateperone LAI X500-E3 IM injection

  • DrugLumateperone LAI

    Lumateperone LAI X500-X2 IM injection

  • DrugLumateperone LAI

    Lumateperone LAI X500-X5 IM injection

  • DrugLumateperone LAI

    Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Cmax,oral

    Maximum plasma concentration of lumateperone

    Time frame: Day 5

  2. Pharmacokinetics: Cmax,IM

    Maximum plasma concentration of lumateperone

    Time frame: Day 11-60

  3. Pharmacokinetics: Tmax,oral

    Time of maximum concentration of lumateperone in plasma

    Time frame: Day 5

  4. Pharmacokinetics: Tmax,IM

    Time of maximum concentration of lumateperone in plasma

    Time frame: Day 11-60

  5. Pharmacokinetics: AUC0-t,oral

    Area under the plasma concentration time curve from time zero to the last measurable of concentration of lumateperone

    Time frame: Day 5

  6. Pharmacokinetics: AUC0-t,IM

    Area under the plasma concentration time curve from time zero to the last measurable of concentration of lumateperone

    Time frame: Day 11-60

Secondary outcomes

  1. Percentage of subjects with treatment-emergent adverse events

    Time frame: up to 30 days after the last protocol-defined study visit

  2. Change from baseline in systolic and diastolic blood pressure

    Time frame: Days 25 and 60

  3. Change from baseline in ECG QTcF interval

    Time frame: Days 25 and 60

  4. Change from baseline in hemoglobin

    Time frame: Days 25 and 60

  5. Change from baseline in white blood cell count

    Time frame: Days 25 and 60

  6. Change from baseline in aspartate aminotransferase

    Time frame: Days 25 and 60

  7. Change from baseline in alanine aminotransferase

    Time frame: Days 25 and 60

  8. Change from baseline in Abnormal Involuntary Movement Scale (AIMS)

    AIMS is a measure of facial and oral movements, extremity movements and trunk movements. Items are rated on a scale from none (0) to severe (4).

    Time frame: Days 25 and 60

07

Study locations

4 sites
  • Collaborative Neuroscience Research, LLC
    Los Alamitos, California 90720, United States
  • CenExeli Research LLC
    Atlanta, Georgia 30030, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Hassman Research Institute, LLC.
    Marlton, New Jersey 08053, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Nov 2025, 14 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2024
First posted
Oct 4, 2024
StartActual
Aug 23, 2024
Primary completionActual
Nov 20, 2025
CompletionActual
Nov 20, 2025
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06627413
Responsible party
Sponsor
First posted
Oct 4, 2024
Start date
Aug 23, 2024
Primary completion
Nov 20, 2025
Completion
Nov 20, 2025
Last update
Jul 31, 2026

Study contacts

Intra-Cellular Therapies, Inc. Clinical Trial
study director · Intra-Cellular Therapies, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion